Compare Torrent Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GSK PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GSK PHARMA TORRENT PHARMA/
GSK PHARMA
 
P/E (TTM) x 58.6 51.6 113.5% View Chart
P/BV x 6.2 10.9 57.1% View Chart
Dividend Yield % 0.8 1.5 56.7%  

Financials

 TORRENT PHARMA   GSK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
GSK PHARMA
Mar-19
TORRENT PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5503,595 43.1%   
Low Rs1,1441,253 91.3%   
Sales per share (Unadj.) Rs354.7184.7 192.1%  
Earnings per share (Unadj.) Rs40.126.3 152.4%  
Cash flow per share (Unadj.) Rs64.229.2 220.2%  
Dividends per share (Unadj.) Rs14.0020.00 70.0%  
Dividend yield (eoy) %1.00.8 126.0%  
Book value per share (Unadj.) Rs273.1126.3 216.2%  
Shares outstanding (eoy) m169.22169.40 99.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.813.1 28.9%   
Avg P/E ratio x33.692.2 36.5%  
P/CF ratio (eoy) x21.083.1 25.2%  
Price / Book Value ratio x4.919.2 25.7%  
Dividend payout %34.976.1 45.9%   
Avg Mkt Cap Rs m227,897410,626 55.5%   
No. of employees `00014.75.0 296.4%   
Total wages/salary Rs m11,3535,372 211.3%   
Avg. sales/employee Rs Th4,083.06,306.7 64.7%   
Avg. wages/employee Rs Th772.31,083.1 71.3%   
Avg. net profit/employee Rs Th461.3898.0 51.4%   
INCOME DATA
Net Sales Rs m60,02131,281 191.9%  
Other income Rs m2,9881,023 292.1%   
Total revenues Rs m63,00932,304 195.0%   
Gross profit Rs m13,4936,009 224.5%  
Depreciation Rs m4,086486 840.7%   
Interest Rs m3,0856 51,413.3%   
Profit before tax Rs m9,3106,540 142.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m2,5292,373 106.6%   
Profit after tax Rs m6,7814,454 152.3%  
Gross profit margin %22.519.2 117.0%  
Effective tax rate %27.236.3 74.9%   
Net profit margin %11.314.2 79.4%  
BALANCE SHEET DATA
Current assets Rs m52,62320,061 262.3%   
Current liabilities Rs m52,02214,543 357.7%   
Net working cap to sales %1.017.6 5.7%  
Current ratio x1.01.4 73.3%  
Inventory Days Days12057 210.6%  
Debtors Days Days7614 542.1%  
Net fixed assets Rs m85,01614,343 592.7%   
Share capital Rs m8461,694 50.0%   
"Free" reserves Rs m45,37619,704 230.3%   
Net worth Rs m46,22221,398 216.0%   
Long term debt Rs m41,1152 2,055,730.0%   
Total assets Rs m142,43239,113 364.2%  
Interest coverage x4.01,091.0 0.4%   
Debt to equity ratio x0.90 951,694.0%  
Sales to assets ratio x0.40.8 52.7%   
Return on assets %6.911.4 60.7%  
Return on equity %14.720.8 70.5%  
Return on capital %14.231.9 44.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,580534 2,730.4%   
Fx outflow Rs m3,6007,091 50.8%   
Net fx Rs m10,980-6,557 -167.5%   
CASH FLOW
From Operations Rs m8,9423,994 223.9%  
From Investments Rs m-47,070-1,433 3,283.8%  
From Financial Activity Rs m34,174-3,584 -953.6%  
Net Cashflow Rs m-3,655-1,023 357.2%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 7.0 10.2 68.8%  
FIIs % 12.6 23.8 52.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 102,036 26.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  SANOFI INDIA  PANACEA BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 17, 2019 02:11 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS